[Shy-Drager disease. Hemodynamic and pharmacodynamic studies. Value of cyproheptadine].
D003533:Cyproheptadine / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D005242:Fecal Incontinence; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy / Q000503:physiopathology; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009461:Neurologic Manifestations; D009886:Ophthalmoplegia; D012701:Serotonin / Q000378:metabolism*; D001750:Urinary Bladder, Neurogenic; D014549:Urinary Incontinence / Q000188:drug therapy
D003533:Cyproheptadine; D012701:Serotonin; D004295:Dihydroxyphenylalanine
A propos d'un cas de maladie de Shy et Drager. Etudes hémodynamiques et pharmacodynamiques. Intérêt de la cyproheptadine.